Evidence map›Paper›PMID 42027418›Full record

ArticleThe Journal of clinical and aesthetic dermatology2026

The Impact of Dupilumab on Psychological Wellbeing in Moderate-to-Severe Atopic Dermatitis Patients: A Phase IV Clinical Trial.

Chandler E Johnson, Kareem G Elhage, Riley K Spencer, Joy Q Jin, Samuel Yeroushalmi, Mitchell S Davis, Marwa Hakimi, Wilson Liao, Tina Bhutani

Registry-linked trialAbstract read
PubMed Full text at PMC
In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03667014 (The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03667014 phase4completednot on this map

The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

TypeinterventionalSponsorUniversity of California, San FranciscoRan2018 to 2022Enrolled34ConditionsAtopic Dermatitis, Atopic Dermatitis EczemaArmsDupilumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chandler E JohnsonAll authors are with the Department of Dermatology at the University of California San Francisco, San Francisco, California.
Kareem G ElhageAll authors are with the Department of Dermatology at the University of California San Francisco, San Francisco, California.
Riley K SpencerAll authors are with the Department of Dermatology at the University of California San Francisco, San Francisco, California.
Joy Q JinAll authors are with the Department of Dermatology at the University of California San Francisco, San Francisco, California.
Samuel YeroushalmiAll authors are with the Department of Dermatology at the University of California San Francisco, San Francisco, California.
Mitchell S DavisAll authors are with the Department of Dermatology at the University of California San Francisco, San Francisco, California.
Marwa HakimiAll authors are with the Department of Dermatology at the University of California San Francisco, San Francisco, California.
Wilson LiaoAll authors are with the Department of Dermatology at the University of California San Francisco, San Francisco, California.
Tina BhutaniAll authors are with the Department of Dermatology at the University of California San Francisco, San Francisco, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aims to prospectively evaluate the emotional impact of dupliumab treatment on patients with atopic dermatitis (AD) using a validated psychometric instrument, the Psychological General Wellbeing (PGWB) index. This index is widely used in nondermatologic conditions and assesses self-representations of intrapersonal affective and emotional states reflecting a sense of subjective wellbeing or distress.

methodsThis was a Phase IV, open-label clinical trial using dupilumab for the treatment of moderate-to-severe AD. The primary endpoint was the change in PGWB score at Week 16 of dupilumab treatment compared to baseline.

resultsA total of 24 participants completed the study. The change in average PGWB score after 16 weeks of treatment with dupilumab compared to baseline was not statistically significant (5.8±19.7; LIMITATIONS: This study did not have a control arm and was limited by small sample size.

conclusionTreatment with dupilumab for 52 weeks was associated with improvement of psychological wellbeing, suggesting that intervention with this interleukin (IL) 4/IL-13 inhibitor is capable of restoring quality of life in these patients. TRIAL ADMINISTRATION: NCT03667014.

Indexed as

Atopic dermatitisclinical trialsdupilumabmental healthquality of life

Identifiers

PMID42027418
PMCPMC13102155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.